title: Topical effects of nebivolol on wounds in diabetic rats.
abstract: OBJECTIVE
  Recently, it has reported that nebivolol might be useful in the treatment of diabetes mellitus foot ulcers. The aim of this study was to examine treatment of the wounds in streptozotocin-induced diabetic rats with topical nebivolol.
  
  
  METHODS
  Two 15 × 15 mm-sized wounds were created in 56 streptozotocin-induced rats. A total of 56 diabetic wounds were studied in eight groups (n=7). No treatment was administered to the first and second groups. The third and fourth groups consisted of diabetic rats that were administered 1:1 mixture of lanolin and vaseline for 7 and 14 days, respectively. Five percent nebivolol plus 1:1 mixture of lanolin and vaseline was administered to rats in the fifth and sixth groups for 7 and 14 days, respectively, and 10% nebivolol plus 1:1 mixture of lanolin and vaseline was administered to rats in the seventh and eighth groups for 7 and 14 days, respectively. On days 7 and 14, wound healing was observed, and the percent of wound healing was determined by measuring its size and histopathologic examination. The ratio was calculated by the formula, healing ratio (%)=100 ×(1-wound area/initial wound area). Statistical analysis was performed by ANOVA with Tukey's HSD test and Mann-Whitney U test, using SPSS 15.0 software.
  
  
  RESULTS
  On days 7 and 14, rates of wound healing in the fifth, sixth, seventh, and eighth groups were 57.42%, 89.16%, 60.80%, and 91.80%, respectively. Multiple comparison showed that rates of wound healing were significantly higher in rats administered 5% and 10% nebivolol than those in rats administered a mixture of lanolin and vaseline and in the untreated group (P<0.05).
  
  
  CONCLUSIONS
  Topical nebivolol therapy may be useful for wound healing in diabetic rats. Further studies are needed to support these data.
authors: Atatürk University, Faculty of Medicine, Department of Internal Medicine and Family Medicine, Turkey. drerimgulcan@gmail.com
authors: Erim
authors: E
authors: Gulcan
authors: Ayşegul
authors: A
authors: Kuçuk
authors: Kasim
authors: K
authors: Çayci
authors: Murat
authors: M
authors: Tosun
authors: Habib
authors: H
authors: Emre
authors: Lokman
authors: L
authors: Koral
authors: Yasemin
authors: Y
authors: Aktan
authors: Umit
authors: U
authors: Avsar
mesh_terms: D000279:Administration, Cutaneous; D058671:Adrenergic beta-1 Receptor Antagonists / Q000008:administration & dosage; D000818:Animals; D001578:Benzopyrans / Q000008:administration & dosage*; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000473:pathology; D017719:Diabetic Foot / Q000188:drug therapy* / Q000473:pathology; D004983:Ethanolamines / Q000008:administration & dosage*; D008297:Male; D000068577:Nebivolol; D051381:Rats; D017208:Rats, Wistar; D014665:Vasodilator Agents / Q000008:administration & dosage; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D058671:Adrenergic beta-1 Receptor Antagonists; D001578:Benzopyrans; D004983:Ethanolamines; D014665:Vasodilator Agents; D000068577:Nebivolol